Form 4: Olema Pharmaceuticals Director Andrew Rappaport Reports Pro Rata Distribution of Common Stock
SEC Form 4 Filing
Director Andrew Rappaport reports a pro rata distribution of Olema Pharmaceuticals common stock from SPW Investments LLC to its members.
Summary
- On March 5, 2024, Andrew Rappaport, a director of Olema Pharmaceuticals, reported a transaction involving the distribution of common stock.
- The transaction involved a pro rata distribution for no consideration from SPW Investments LLC (SPWI) to its members.
- Rappaport indirectly acquired 385,965 shares and disposed of 481,014 shares of common stock.
- Following the transaction, Rappaport indirectly owns 385,965 shares through the Rappaport Family Trust and 0 shares through SPWI.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing, reporting a pro rata distribution of shares. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company insiders.
Key Dates
| Date | Description |
|---|---|
| 03/05/2024 | Date of transaction: pro rata distribution of common stock. |
| 03/06/2024 | Date of signature by Attorney-in-Fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.